This review summarises the evidence supporting the use of Synthroid® (levothyroxine) for the treatment of hypothyroidism. The partnership between primary care and the patient is essential to achieving stable thyroid function. Synthroid® is fully funded and available in three tablet strengths (25, 50 and 100 mcg). NICE recommends bodyweight dosing of levothyroxine to the nearest 25 mcg and Synthroid® is the only brand with a 25-mcg tablet that is both Medsafe-approved and Pharmac-funded. This review is sponsored by an educational grant from Viatris.
Please login below to download this issue (PDF)